Cameron Health Inc.
This article was originally published in Start Up
Executive Summary
Cameron Health believes that the market for implantable cardiac defibrillators (ICDs) is underpenetrated because of the complexity involved in implanting and programming current devices. The company's cardiologist founders created an implantable device that effectively terminates ventricular defibrillation, without using leads that contact the heart directly. Heart leads are the weakest link of current devices, since they can break, become dislodged, or incur infection, Cameron's Health device, which can be implanted subcutaneously in a ten minute procedure should help electrophysiologists handle a higher volume of patients and enable cardiologists to get a share of the procedures as well.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.